The Swamp logo

How a "Strong Dollar" Destroyed America's Ability to Make Medicine

90% of active pharmaceutical ingredients are imported.

By Elliott J. SchuchardtPublished 2 days ago • Updated 2 days ago • 4 min read
How a "Strong Dollar" Destroyed America's Ability to Make Medicine
Photo by Jorge Campos on Unsplash

Walk into any pharmacy in the United States, and you will find shelves stocked with life-saving medications. Behind the familiar packaging lies a dangerous reality: the United States no longer makes the ingredients for the drugs it needs to treat its citizens.

It was not always this way. In 1970, the United States was the undisputed powerhouse of global pharmaceutical manufacturing. Back then, American chemical plants produced 80% to 90% of the core ingredients for medicines used in the United States. These are known as Active Pharmaceutical Ingredients (APIs). Even through the early 1990s, America and Western Europe dominated the production of the foundational chemical compounds that make medicines work.

Over the past three decades, that industrial capacity has hollowed out. Today, nearly 88% of the APIs used in American prescription drugs are manufactured overseas - primarily in India and China. Even when a medication is stamped "Made in the USA," it often means only that imported chemical powders were pressed into tablets and bottled on American soil.

The numbers for specific, everyday medications are staggering. According to industry and federal trade analyses, China alone supplies roughly 90% to 95% of U.S. imports of ibuprofen, 91% of hydrocortisone, 82% of tetracycline antibiotics, 74% of vitamin C, 70% to 72% of acetaminophen, and up to 45% of penicillin. Furthermore, even when generic APIs are finished in India or Europe, the raw chemical building blocks—known as key starting materials—overwhelmingly originate in China. For instance, all four raw materials required to make amoxicillin, one of America's most prescribed antibiotics, come primarily from Chinese factories.

In 2025, Washington, D.C. finally woke up to the critical vulnerabilities posed by the problem. In 2025 and 2026, the federal government took aggressive steps to rebuild domestic drug capacity. The White House issued executive orders to fill the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR) with a six-month stockpile of critical drug ingredients. The Food and Drug Administration launched the "FDA PreCheck" program to fast-track the approval of new domestic factories. Meanwhile, other federal agencies used the Defense Production Act to promote programs such as ReShoreRx, to bring critical medicines back to American soil.

While well-intentioned, these measures miss the root cause of the crisis. As I argue in my book, America’s Achilles Heel: How to Protect Your Family When America Loses the Reserve Currency, the offshoring of vital industries is not merely a failure of corporate patriotism or regulatory red tape. It is the inevitable mathematical consequence of an artificially overvalued U.S. dollar.

To understand why American factories cannot compete in making basic pharmaceutical ingredients, we have to look at the mechanics of global currency markets—specifically, the petrodollar system. Since the 1970s, the United States has maintained an arrangement in which global oil sales are priced and settled almost exclusively in U.S. dollars. Because every nation on earth needs energy to power its economy, central banks and corporations around the globe must constantly acquire and hold vast reserves of dollars just to buy oil.

This perpetual, forced global demand acts like an invisible weight pressing upward on the value of the American currency. Under normal economic conditions, if a country runs massive trade deficits year after year, its currency naturally weakens, making its exports cheaper and reviving domestic factories. However, the petrodollar monopoly short-circuits this natural self-correction. Even as the United States imports far more than it exports, relentless international demand for energy transactions keeps the dollar artificially strong.

For American manufacturers, a chronically overvalued currency acts as a permanent, crippling tariff on domestic production. Building and operating an API facility in Ohio, North Carolina, or Tennessee requires heavy capital investment, strict environmental compliance, and skilled labor. When the U.S. dollar is priced 20% to 40% higher than its true competitive equilibrium, foreign competitors operating with undervalued currencies can produce the exact same chemical compounds and ship them across the ocean for a fraction of the cost in dollar terms. Faced with skewed exchange rates, pharmaceutical companies shifted their supply chains abroad out of basic financial survival.

This structural distortion is a ticking time bomb for the American economy: what happens if the dollar suddenly loses its reserve status and collapses?

If the petrodollar system unravels and the dollar plunges in value overnight, America’s purchasing power on the global market would evaporate. Foreign suppliers in China and India—who hold no allegiance to American patients—would demand payment in hard commodities, gold, or stronger regional currencies before shipping a single barrel of chemical precursors. Overnight, the cost of imported APIs would skyrocket beyond what American hospitals, insurers, and families could afford. Because we dismantled our domestic chemical plants decades ago, we could not simply flip a switch to make these ingredients at home. Building new FDA-approved API facilities takes years of construction, specialized engineering, and regulatory clearance. In a currency collapse, America would find itself unable to buy foreign medicine and unable to manufacture its own.

Throwing taxpayer subsidies at a handful of drugmakers will not fix this existential threat. As long as the exchange rate heavily penalizes American labor and domestic production, any factory built with government grants will remain uncompetitive without endless federal life support.

We cannot bring pharmaceutical manufacturing back to the United States—and we cannot protect our economy from a future currency shock—until we address the root distortion. Restoring our industrial base requires an orderly, deliberate devaluation of the U.S. dollar to bring it back in line with economic reality, much like the 1985 Plaza Accord that successfully revived American manufacturing exports. Until Washington dismantles the structural forces keeping the dollar artificially inflated, America’s economy and medicine cabinet will remain at the mercy of foreign powers.

_____________

Elliott Schuchardt is the author of America’s Achilles Heel: How to Protect Your Family When America Loses the Reserve Currency. In 2026, Schuchardt was a candidate for the Tennessee General Assembly.

congressnew world ordertradefinancepoliticsactivismcorruption

About the Creator

Elliott J. Schuchardt

Elliott Schuchardt is the author of America's Achilles Heel: How to Protect Your Family When America Loses the Reserve Currency. Schuchardt was a candidate for the Tennessee General Assembly in the August 2026 primary. Follow my blog.

Enjoyed the story? Support the Creator.

Subscribe for free to receive all their stories in your feed.

Subscribe For Free

Reader insights

Comments

There are no comments for this story

Be the first to respond and start the conversation.

Sign in to comment
    Written by Elliott J. Schuchardt